Cistron Biotechnology(CIST)$.30 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (761)	7/9/1997 2:57:00 PM
From: Rudy Saucillo	of 2742

Rick, Xytronyx (XYX) has a recently approved product that will likely compete with CIST's periodontal disease assay. Here's the URL of the news announcement and a brief excerpt: biz.yahoo.com "The PTM Kit detects elevated levels of aspartate aminotransferase (AST) associated with tissue necrosis. It is intended to be used as an objective, biochemical adjunct to traditional methods of monitoring patients to assist in the decision to apply treatment and in the evaluation of treatment effectiveness." From this description, it appears that XYX's approach to detecting periodontal disease is fundamentally different than CIST's (see abstract in reply #709). My layman's interpretation leads me to think that XYX's product detects late-stage (i.e., tissue necrosis stage) damage while CIST's detects early stage disease. Comments? XYX supposedly will begin shipping in the U.S. later this year. It'll be interesting to watch their sales. Also, XYX apparently had quite a bit of trouble with the FDA and then with their shareholders. Again, here's a URL for the story and an excerpt: sddt.com "Impatient shareholders sued the company in 1992 alleging it failed to disclose problems with approval from the U.S. Food and Drug Administration (FDA) for Xytronyx's PerioGard Periodontal Tissues Monitor Kit, which Xytronyx claims can help dentists better identify sites of gum disease. The kit is supposed to facilitate testing for active periodontal disease on a tooth-by-tooth basis, allowing the clinician to treat only those teeth with active disease. A settlement to the class action litigation was announced in March 1994. It called for payment of $2.8 million, which was paid by the company's insurers, and issuance to the plaintiffs of 307,734 common shares with an exercise price of $22 per share on five-year warrants." Cheers! Rudy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next